Formycon AG
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
18.81%
Market Cap
362.29 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-3.66 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 20.65 G | 0 Units |
| PRICE DETERMINATION TIME | 06/04/2026 / 07:31:13 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 20.7 | 20.2 |
| PREV. DAY'S PRICE | 20.5 | (06/03) |
| CHANGE DAY BEFORE | +0.15 | 0.73 % |
| 52 WEEK HIGH / LOW | 31.05 (07/28) | 16.16 (03/23) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 1.27 | -0.56 | -3.66 | -7.18 | 4.76 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | 17.80 | - | - | - | 11.84 |
| PRICE - BOOK RATIO | - | - | 1.13 | 2.03 | 1.80 |
| PRICE - SALES RATIO | - | - | 10.17 | 13.33 | 11.65 |
| PRICE - CASH FLOW RATIO | - | - | 39.25 | - | - |
Master Data
| WKN | A1EWVY |
| ISIN | DE000A1EWVY8 |
| SYMBOL | FYB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | Formycon AG |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 17.67 Mil. |
| MARKET CAPITALISATION | 362.29 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.24 % | 13.64 % | -3.98 % | -14.05 % | -18.81 % | -71.33 % | -66.12 % | -20.23 % |
| HIGH | 22.55 | 22.55 | 22.55 | 26.55 | 31.05 | 71.70 | 92.50 | 26.55 |
| LOW | 19.76 | 17.54 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 | 16.16 |
Dividend
per share
Formycon AG does not deliver dividend information
Company profile
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
Structured products for Formycon AG
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 6 days)
06/10/26Annual General Meeting
(in 14 days)
06/18/26UBS Life Sciences Conference
(in 27 days)
07/01/26Q1 2026 Earnings Release
(in 69 days)
08/12/26Q2 2026 Earnings Release
(in 102 days)
09/14/26H.C. Wainwright Global Investment Conference